secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001171843-23-001657
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q4 net loss $74M; botensilimab shows 23% ORR in MSS CRC, 50% in NSCLC
----------------------------------------------------------------------------

- Q4 2022 revenue $28.4M, net loss $74.1M ($0.24/sh); FY22 revenue $98M, net loss $230.7M ($0.78/sh).
- Cash & short-term investments $193M at Dec 31, 2022, down from $307M a year earlier.
- Botensilimab/balstilimab combo: 23% ORR in MSS CRC (70 evaluable), 50% ORR in PD-(L)1 refractory NSCLC (8 evaluable).
- Phase 3 confirmatory trial in MSS CRC expected in 2023; randomized Phase 2 ACTIVATE studies ongoing.
- Potential future milestones from collaborations up to $2.7B; nine new partner trials launched in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000117184323001657/0001171843-23-001657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000117184323001657/f8k_031423.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer